Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + lenalidomide + dexamethasone for relapsed/refractory multiple myeloma on lenalidomide maintenance (W-JHS MM02)
jRCTs071190019Completed
- Sponsor
- Takeda
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Takeda. Primary endpoint: Very good partial response (VGPR) or better rate within 12 cycles. Started Oct 2020; status: completed.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071190019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190019.